研究单位：[1]Daiichi Sankyo,Inc.[2]University of Electronic Science & Technology of China (UESTC) - Sichuan Cancer Hospital & Institute (Sichuan Provincial Tumor Hospital Chengdu,China,610041[3]Mount Sinai Hospital New York,New York,United States,10029[4]Memorial Sloan Kettering Cancer Center New York,New York,United States,10065[5]Levine Cancer Institute Charlotte,North Carolina,United States,28204[6]Cleveland Clinic - Main Campus Cleveland,Ohio,United States,44195[7]Providence Portland Medical Center Portland,Oregon,United States,97213[8]Sarah Cannon Research Institute at Tennessee Oncology - Chattanooga Chattanooga,Tennessee,United States,37404[9]Sarah Cannon Research Institute Nashville,Tennessee,United States,37203[10]University of Virginia Cancer Center - Emily Couric Clinical Cancer Center Charlottesville,Virginia,United States,22903
研究目的：
This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an activating EGFR mutation (exon 19 deletion or L858R) who have received and progressed on or after at least 1 EGFR TKI and 1 platinum-based chemotherapy-containing regimen.
